Next Article in Journal
Isolation, Characterization and Biological Evaluation of Collagen from Rhizostoma pulmo Jellyfish from the Sea of Azov for Biomedical Applications
Next Article in Special Issue
Chlokamycins B–D: Chlorohydrin-Containing Polycyclic Tetramate Macrolactams with Cytotoxic Activity from the Marine Sponge-Derived Streptomyces xiamenensis 1310KO-148
Previous Article in Journal
Microalgal Exosome-like Nanovesicles from Nannochloropsis oculata Attenuate Melanogenesis Through Tyrosinase Inhibition in B16-F10 Melanoma Cells
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Novel Marine Fungus-Derived Mycophenolic Acids That Inhibit Acute Myeloid Leukemia Cell Proliferation

1
Research Center for Deepsea Bioresources, Sanya 572025, China
2
State Key Laboratory of Chemical Biology, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai 201203, China
3
South China Sea Institute of Oceanology, Chinese Academy of Sciences, Guangzhou 510301, China
*
Authors to whom correspondence should be addressed.
These authors contributed equally to this work.
Mar. Drugs 2026, 24(3), 108; https://doi.org/10.3390/md24030108
Submission received: 21 February 2026 / Revised: 10 March 2026 / Accepted: 12 March 2026 / Published: 13 March 2026
(This article belongs to the Special Issue Bioactive Secondary Metabolites from Marine Fungi and Actinomycetes)

Abstract

Nine new mycophenolic acid derivatives, penicacids O–W (19), two first-time reported natural products (10, 11), and five known compounds (1216), were isolated from a marine-derived fungus Penicillium senticosum RCDB005 found in a South China Sea sediment sample. Their structures were determined using NMR, HRESIMS, and optical rotatory dispersion (ORD) spectra, electronic circular dichroism (ECD) calculations, X-ray crystallography, and modified Mosher’s methods. Eight of these compounds were evaluated for anti-proliferative effects against nine human cancer cell lines and the IC50 values ranged from nM to μM levels. Compounds 5, 79 showed potent inhibition activity against MOLM-13 acute myeloid leukemia cells with IC50 values between 0.13 and 1.13 μM.

Graphical Abstract

1. Introduction

With great advantages of unique ecological environments, powerful gene clusters, and high yields of secondary metabolites, marine-derived fungi represent a gigantic and untapped reservoir for the exploration of novel bioactive marine natural products (MNPs). They offer immense potential in cancer treatment due to their diverse mechanisms of action, such as cytotoxic, antiproliferative, and immunomodulatory properties [1]. As a representative example, fucoxanthin (C42H58O6), found in brown algae such as Undaria pinnatifida, reduces leukemia and breast cancer cell growth [2]. Similarly, highly oxygenated polyketides, aspergilsmins A–G were isolated from Aspergillus giganteus NTU967 obtained from Ulva lactuca. Among them, aspergilsmin C and patulin exhibited significant inhibitory effects on prostate cancer PC-3 cells and human hepatocellular carcinoma SK-Hep-1 cells, with IC50 values ranging from 2.7 to 7.3 μM [3]. Importantly, marine-derived compounds have shown a broad spectrum of anticancer activities, including some that are resistant to conventional chemotherapy. These compounds offer a unique and largely untapped source of chemical diversity that can be exploited in the search for new and effective cancer treatments. This has led to a growing body of research focused on the discovery and development of marine-derived anticancer drugs, with many compounds undergoing preclinical and clinical evaluation [4].
One promising family of MNPs is mycophenolic acids (MPAs), mainly found in several Penicillium species [5,6]. MPA (13) is a potent inhibitor of human inosine 50-monophosphate dehydrogenase (IMPDH), a key enzyme in de novo biosynthesis of guanine nucleotides [7]. Since the discovery of MPA as a secondary fungal metabolite in 1893 [8], this compound and its derivatives have received widespread attention due to their broad bioactivities, such as immunosuppressive, antibacterial, antifungal, antiviral, and antitumor properties. Because of the potent bioactivity, many derivatives of MPA were investigated for drug development, and one derivative, mycophenolate mofetil (MMF), has been approved as an immunosuppressant and widely used in kidney, heart, and liver transplantation patients [9,10,11].
The aim of this study was to explore the secondary metabolites produced by Penicillium senticosum RCDB005 from a South China Sea sediment sample under laboratory conditions (solid-substrate fermentation cultures) in order to identify new bioactive substances.

2. Results and Discussion

Compound 1 was isolated as a white powder. The molecular formula was deduced as C16H18O5 based on the (+)-HRESIMS ion at m/z 291.1224 [M+H]+ (calcd for C16H19O5, 291.1227), indicating eight degrees of unsaturation. The 1H, 13C NMR (Table 1), DEPT and HSQC spectra revealed the presence of two carbonyl carbons (δC 212.3, C-4′; 171.4, C-1), six aromatic quaternary carbons (δC 161.7, C-5; 158.7, C-7; 148.8, C-3a; 117.0, C-6; 116.3, C-4; 102.9, C-7a), one oxygen-bearing methine (δC/H 88.0/5.13, C-2′), one methine (δC/H 52.4/3.08, C-3′), one methylene group (δC/H 32.3/3.58, 3.21, C-1′), an oxygenated aliphatic methylene group (δC/H 70.7/5.22, C-3), one aromatic methyl group (δC/H 11.0/2.06, C-8), one aromatic methoxyl group (δC/H 59.7/4.00, 5-OCH3), and two aliphatic methyl groups (δC/H 29.8/2.27 C-5′; 12.1/1.16, C-6′). These data showed a close similarity to those reported for 2-(4-methoxy-5-methyl-8-oxo-2,3,6,8-tetrahydrobenzo [1,2-b:5,6-c′] difuran-2-yl) propanoic acid isolated from Penicillium sp. SCSIO sof101 [12], and then 1 was inferred to be an analog. Detailed analysis of 1D NMR (Table 1), HSQC, HMBC and 1H-1H COSY spectra (Figure 1) revealed that the major difference was the shift in the 4′-carbonyl carbon to the low field, suggesting that a methyl substitution may occur at the 4′-hydroxyl group, which was confirmed by the HMBC correlations from H-5′ to C-4′ and C-3′, from H-6′ to C-4′ and C-2′, from H-1′ to C-6 and C-7, from 5-OCH3 to C-5, from H-8 to C-3a, C-4, and C-5, from H-3 to C-1, C-3a, C-4 and C-7a. In addition, COSY correlations of H2-1′/H-2′/H-3′/H-6′ were observed, displaying the linkage between the carbons directly connected to the protons. Thus, the planar structure of 1 was established as shown (Figure 2) and named penicacid O.
The theoretical ECD curve of 1 was then calculated and compared with the experimental ECD curve. The experimental ECD curve of 1 showed a higher similarity to the calculated ECD curve of (2′R, 3′R)-1 (Figure 3). Finally, the absolute configuration of 1 was confirmed as 2′R, 3′R by X-ray crystallographic analysis (Figure 4), and the compound was named penicacid O (Figure 2).
Compound 2 was isolated as a white powder with the same molecular formula as that of 1 according to (+)-HRESIMS data, implying eight degrees of unsaturation. Their 1H, 13C NMR (Table 1) and DEPT data were quite similar, suggesting 2 may be an enantiomer of 1. According to the 1D and 2D NMR data (Table 1 and Figure 1), the planar structure of 2 was established, and the compound was designated as penicacid P.
The theoretical ECD curve of 2 was then calculated and compared with the experimental ECD curve. The experimental ECD curve of 2 showed a higher similarity to the calculated ECD curve of (2′S, 3′S)-2, and the experimental ECD curve of 2 was completely opposite to the experimental ECD curve for 1 (Figure 3), suggesting that 2 was an enantiomer of 1, which was further supported by the NOESY correlation between H-1′ and H-6′ in both 1 and 2 (Figure 1). Accordingly, the absolute configuration of 2 was identified as 2′S, 3′S (Figure 2).
Compound 3 was isolated as a white powder with the same molecular formula as that of 1 according to (+)-HRESIMS data, implying eight degrees of unsaturation. The 1H, 13C NMR (Table 1) and DEPT data of 3 closely resembled those of 1. The major difference was that the chemical shift in methyl group (δC/H 12.7/1.28, recorded in CD3OD) attached to C-6′ in 3 was downfield shifted with respect to that in 1 (δC/H 12.1/1.16, recorded in CD3OD), suggesting 3 was a diastereomer at C-2′ or C-3′ of 4. According to the 1D and 2D NMR data (Table 1 and Figure 1), the planar structure of 3 was established, and the compound was designated as penicacid Q.
The theoretical ECD curve of 3 was then calculated and compared with the experimental ECD curve. The experimental ECD curve of 3 showed a higher similarity to the calculated ECD curve of (2′S, 3′R)-3 (Figure 3). Accordingly, the absolute configuration of 3 was identified as 2′S, 3′R (Figure 2).
Compound 4 was isolated as a white powder with the same molecular formula as that of 1 according to (+)-HRESIMS data, implying eight degrees of unsaturation. Their 1H, 13C NMR (Table 1) and DEPT data were quite similar, suggesting 4 may be an enantiomer of 3. According to the 1D and 2D NMR data (Table 1 and Figure 1), the planar structure of 4 was established, and the compound was designated as penicacid R.
The theoretical ECD curve of 4 was then calculated and compared with the experimental ECD curve. The experimental ECD curve of 4 showed a higher similarity to the calculated ECD curve of (2′R, 3′S)-4, and the experimental ECD curve of 4 was completely opposite to the experimental ECD curve for 3 (Figure 3), suggesting 4 was an enantiomer of 3. Accordingly, the absolute configuration of 4 was identified as 2′R, 3′S (Figure 2).
Compound 5 was obtained as yellow oil. The molecular formula was deduced as C18H20O6 based on the (+)-HRESIMS ion at m/z 333.1350 [M+H]+ (calcd for C18H21O6, 333.1333), indicating nine degrees of unsaturation. The 1H, 13C NMR (Table 2), DEPT and HSQC spectra revealed the presence of two ester carbonyls (δC 169.2, C-1; 172.0, C-6′), six aromatic quaternary carbons (δC 159.9, C-5; 158.1, C-7; 147.2, C-3a; 116.2, C-6; 114.9, C-4; 102.7, C-7a), one oxygenated sp3 methine (δC/H 90.1/5.40, C-2′), two methylene [including one oxygenated methylene (δC/H 69.2/5.13, C-3)] and four methyl groups [including two oxygenated methine groups (δC/H 59.3/3.95, 5-OCH3; 52.1/3.70, C-8′)]. These data showed a close similarity to those reported for compound 2 from Penicillium sp. HN 66 [13], and then 5 was inferred to be an analog. Detailed analysis of 1D NMR (Table 2), HSQC, HMBC and 1H-1H COSY spectra (Figure 1) revealed that the major difference was the shift of the C-4′ carbon to the low field and shift of the C-2′ carbon to the high field, suggesting the possibility that after opening the ∆2′ double bond on compound 16, it reacted not only with the 4′-hydroxyl group to remove one molecule of H2O and form the ∆3′ double bond, but also with the 7-hydroxyl group to form a five-membered ring, as confirmed by the HMBC correlations from H-7′ to C-4′, C-3′ and C-2′, from H-1′ to C-6 and C-7, from H-8′ to C-6′, from H-5′ to C-6′, from 5-OCH3 to C-5, from H-8 to C-3a, C-4, and C-5, and from H-3 to C-1, C-3a, C-4 and C-7a. In addition, COSY correlations of H2-1′/H-2′ and H-4′/H2-5′ were observed, revealing the linkage between the carbons directly connected to the protons. Thus, the planar structure of 5 was established as shown (Figure 2) and named penicacid S. According to NOESY data correlation between H2-5′ and H3-7′, the double bond is in E-geometry (Figure 1).
Compound 6 was isolated as yellow oil with the same molecular formula as that of 5 according to (+)-HRESIMS data, implying nine degrees of unsaturation. Their 1H, 13C NMR (Table 2) and DEPT data were quite similar. According to the 1D and 2D NMR data (Table 2 and Figure 1), the planar structure of 6 was established, and the compound was designated as penicacid T. According to NOESY data (Figure 1), the double bond in 6 has an E configuration, which is confirmed by the correlation of H2-5′/H3-7′.
The theoretical ECD curves of 5 and 6 were then calculated and compared with the experimental ECD curves. Compound 5 showed a higher similarity to the calculated ECD curve for 2′S. Accordingly, the absolute configuration of 5 was identified as 2′S (Figure 5). And the experimental ECD curve of 6 was completely opposite to the experimental ECD curve for 5 (Figure 5). Accordingly, the absolute configuration of 6 was identified as 2′R (Figure 5).
Compound 7 was obtained as yellow oil. The molecular formula was deduced as C19H24O7 based on the (+)-HRESIMS ion at m/z 387.1414 [M+Na]+ (calcd for C19H24O7Na, 387.1414), indicating eight degrees of unsaturation. Careful comparison of the 1D NMR data of 7 and penicacid N revealed a high structural similarity except for the appearance of an oxyethyl group (δC/H 60.9/4.13, C-8′; 14.3/1.24, C-9′) in 7 instead of the methoxy group at C-6′ in penicacid N [13]. 1H-1H COSY correlations of H2-8′/H-9′ were observed, revealing the linkage between the carbons directly connected to the protons. The location of the oxyethyl group at C-6′ in 7 was confirmed by the HMBC correlation from H-8′ to C-6′ (δC 172.8). Additionally, the key HMBC correlations from H-5′ to C-6′, from H-4′ to C-2′, from H-7′ to C-2′ and C-4′, from H-1′ to C-3′, C-5, C-6 and C-7, from 5-OCH3 to C-5, from H-8 to C-3a and C-4, and from H-3 to C-1, C-3a, C-4 and C-7a further supported the planar structure of 7 (Figure 2), which was elucidated as 4′S-hydroxy-6′-ethoxy mycophenolic acid and named penicacid U. According to NOESY data correlation between H2-1′ and H3-7′, the double bond is in E-geometry (Figure 1).
The configuration at C-4′ was determined by a modified Mosher’s method [14,15,16]. Firstly, the phenol group of compound 7 was methylated by TMSCHN2 [7]. Then, the (S)- and (R)-MTPA esters of 7, 7a and 7b were obtained by acylation of 7 with (R)- and (S)-MTPA-Cl, respectively. According to the rule of the modified Mosher’s method, a 4′S configuration in 7 was inferred from the ΔδH values (ΔδH = δS-MTPA-esterδR-MTPA-ester) of the hydrogen signals adjacent to C-4′ (Figure 6). Thus, the absolute configuration of 7 was established as 4′S (Figure 2).
Compound 8 was obtained as yellow oil. The molecular formula was deduced as C20H24O8 based on the (+)-HRESIMS ion at m/z 415.1373[M+Na]+ (calcd for C20H24O8Na, 415.1363), indicating nine degrees of unsaturation. After comparing its NMR data with those of penicacid N [13], compound 8 was determined to have an identical planar structure to penicacid N. However, the optical rotatory dispersion (ORD) value of compound 8 was −10°, which was opposite to the ORD value of penicacid N [ α ] D 25 = +8 (c 0.1, MeOH). This discrepancy suggests that the configuration of the C-4′ position in compound 8 is opposite to that of penicacid N. The ECD spectrum of 8 (Figure 5) shows a negative Cotton effect at 205 nm, as opposed to penicacid N. The absolute configuration of chiral center 4′S was determined by comparing the experimental and calculated ECD spectra (Figure 5). According to NOESY data correlation between H2-1′ and H3-7′, the double bond is in E-geometry (Figure 1). Consequently, the structure of 8 was elucidated as 4′S-methyl acetate-6′-methoxy mycophenolic acid and named penicacid V.
Compound 9 was obtained as yellow oil. The molecular formula was deduced as C20H24O8 based on the (+)-HRESIMS ion at m/z 415.1373[M+Na]+ (calcd for C20H24O8Na, 415.1363), indicating nine degrees of unsaturation. This suggests that compound 9 should have an identical chemical formula as compound 8. The most notable difference observed in the NMR data (1D NMR in Table 3; HSQC, HMBC, and 1H-1H COSY in Figure 1) was an upfield shift for C-4′ and a downfield shift for C-7′. This shift pattern implies that the methyl acetate group in compound 8 may have been repositioned as confirmed by the HMBC correlations from H-7′ to C-9′, C-4′, C-3′ and C-2′. Additionally, the key HMBC correlations from H-10′ to C-9′, from H-8′ to C-6′, from H-5′ to C-6′, from H-4′ to C-2′, from H-1′ to C-3′, C-5, C-6 and C-7, from 5-OCH3 to C-5, from H-8 to C-3a and C-4, and from H-3 to C-1, C-3a, C-4 and C-7a further supported the planar structure of 9. In addition, the COSY correlations of H2-1′/H-2′ and H2-4′/H2-5′ were observed, revealing the linkage between the carbons directly connected to the protons. Thus, the planar structure of 9 was established as shown (Figure 2), elucidated as 6′-methoxy-7′-methyl acetate mycophenolic acid and named penicacid W. According to NOESY data correlation between H2-1′ and H2-7′, the double bond is in Z-geometry (Figure 1).
Compound 10 was obtained as yellow oil and determined to be C17H20O6 based on the (-)-HRESIMS. The planar structure of 10 was the same as a synthesized compound methyl-6-(4,6-dihydroxy-7-methyl-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate (10) by 1D and 2D NMR spectra (Table S1 and Figure S1) [17]. The double bond of 10 was identified as in E-geometry by NOESY data correlation between H2-1′ and H3-7′ (Figure S2). Notably, compound 10 was isolated from a natural source for the first time.
Compound 11 was isolated as yellow oil, and the molecular formula was determined as C17H20O6 by (-)-HRESIMS. The 1D and 2D NMR data (Table S1 and Figure S1) showed the same planar structure as a synthesized compound methyl (E)-6-(4-hydroxy-6-methoxy-3-oxo-1,3-dihydroisobenzofuran-5-yl)-4-methylhex-4-enoate [18]. Compound 11 was often synthesized but has never been isolated from natural sources. According to NOESY data correlation between H2-1′ and H3-7′, the double bond is in E-geometry (Figure S3).
Five known compounds were compared of their spectrometric data with those in the literature and identified as penicacid L (12) [13], mycophenolic acid (13) [19], 4′-hydroxy-MPA (14) [20], methyl mycophenolic acid (15) [21], and penicacid M (16) [13]. Among them, the double bond of 12 is in E-geometry by X-ray crystallographic analysis (Figure 3).
All the isolated compounds were evaluated for their anti-proliferative effects against human acute myeloid leukemia cells (OCI-AML3) using the CCK-8 method. Among them, compounds 5, 79 and 1316 showed potent inhibitory activity, while the remaining eight compounds had IC50 values above 40 μM (Table S2). Compounds 5, 79 and 1316 were subsequently assessed against a panel of human tumor cell lines derived from leukemia, lymphoma, colon cancer, and pancreatic cancer. As shown in Table 4, all of them displayed a broad spectrum of anti-proliferative effects with IC50 values ranging from 60 nM to more than 40 μM, but the inhibition was weaker than that of commonly used chemotherapeutic agent doxorubicin. MOLM-13 (human acute myeloid leukemia), MOLT-3 (human T cell leukemia), and OCI-AML3 (human acute myeloid leukemia) cells were particularly sensitive to these compounds, with 5, 7 and 8 exhibiting stronger inhibition than MPA (13) in MOLM-13 cells. In contrast, the human pancreatic cell line BXPC3 showed the lowest sensitivity. Compound 9 had the weakest anti-proliferative effect against tumor cells, with IC50 values above 40 μM in four out of eight cell lines.

3. Materials and Methods

3.1. General Experiment Procedures

Optical rotations were taken on a Rudolph Research Analytical Autopol III polarimeter (Rudolph Research Analytical, Hackettstown, NJ, USA). The UV spectra were recorded on an Evolution 350 UV–Vis spectrometer (ThermoFisher Scientific, Madison, WI, USA). ECD data were measured on a Chirascan V100 spectrometer (Applied Photophysics, Leatherhead, Surrey, UK). The NMR spectra were recorded on Bruker 600 MHz NMR spectrometers (Bruker AG, Zürich, Switzerland), while HRESIMS data were obtained using Agilent 6520 and 6545 Q-TOF LC-MS spectrometers (Agilent Technologies, Singapore). Crystal data were obtained on a Bruker D8 Single-Crystal X-Ray Diffractometer (Bruker AXS, Karlsruhe, Germany). The separation and purification of the isolated compounds were carried out using the Agilent 1260 and 1290 HPLC (Agilent Technologies, Waldbronn, Germany) equipped with a 250 mm × 10 mm i.d., 5 μm, Titank C18 column (FLM, Guangzhou, China). The other chromatographic columns used included a 250 mm × 4.6 mm i.d., 5 μm, Chiral NQ(2)-RH column (FLM) and 250 mm × 10 mm i.d., Pursuit 5 PFP column (Agilent, Santa Clara, CA, USA). Medium pressure liquid chromatography (MPLC) separations were performed on a Buchi Sepacore® X50 (BUCHI Labortechnik AG, Flawil, Switzerland) using a C18 column (SW-5222-120-SP, Santai Technologies, Changzhou, China) and glass columns filled with 300–400 mesh silica gel (Qingdao Marine Chemical Factory, Qingdao, China). The solvents and culture media utilized were sourced from Sinopharm Chemical Reagent Co., Ltd. (Shanghai, China), while the deuterated solvents were obtained from Cambridge Isotope Laboratories, Inc. (Shanghai, China). Deuterated solvents used for NMR were CDCl3 (δH 7.260/δC 77.160) and CD3OD (δH 3.310/δC 49.000). (Trimethylsilyl)diazomethane was procured from Shanghai McLean Biochemical Technology Co., Ltd. (Shanghai, China). (R)- and (S)-MTPA-Cl ((S)-(+)-a-methoxy-a-(trifluoromethyl)phenylacetyl chloride) were procured from Shanghai Aladdin Biochemical Technology Co., Ltd. (Shanghai, China).

3.2. Microbial Materials and Fermentation

The fungal strain RCDB005 was isolated from the sediments collected at a depth of 1400 m in the South China Sea and identified as Penicillium senticosum (accession No. PX069401) based on ITS region sequences. Strain RCDB005 was cultured on MB (malt extract powder 15 g, sea salt 15 g, H2O 1 L, 15 g agar, pH 7.4–7.8) agar plates for 3 days before inoculation into MB seed liquid (without agar), which was incubated at 28 °C on a rotary shaker at 180 rpm for 2 days. The seed liquid was then transferred to sterile rice medium (rice 200 g, 1.5% sea salt water 200 mL, per bottle), and large-scale fermentation was performed in 100 flasks at 25 °C for 31 days.

3.3. Extraction and Isolation

The rice culture of RCDB005 was broken by ultrasonication and transferred to a vat, soaked in 60 L of EtOAc overnight, the extraction was repeated three times, and the solvent was evaporated to obtain a crude (207.8 g). The crude was filtered to remove spores and insoluble matter and extracted with MeOH and PE three times to obtain the de-oiled methanolic fraction (122.3 g). The methanolic fraction was first extracted with DCM–PE (1:9, 3:7, 5:5, 7:3, 9:1, 1:0, v/v, per 3.0 L) and DCM–MeOH (1:9, 3:7, 5:5, 7:3, 1:0, v/v, per 6.0 L). Gradient elution of the de-oiled crude was subjected to silica gel column chromatography, and five fractions (Fr. 1–Fr. 5) were obtained. Fraction Fr. 1 (20.5 g) was subjected to MPLC with MeOH and H2O (2:8–1:0, v/v, per 2.0 L). Subfraction Fr. 1-1 (633.0 mg) was isolated and purified by preparative HPLC with a Titank C18 column (55% ACN in H2O, v/v, 2 mL/min) to give compound 12 (3.1 mg, tR = 31 min) and mixture S7. Mixture S7 (30.0 mg) was isolated and purified by analytical HPLC with a chiral column (70% MeOH in H2O, v/v, 0.8 mL/min) to give compounds 1 (2.3 mg, tR = 33 min), 2 (2.0 mg, tR = 20 min), 3 (1.0 mg, tR = 16 min), and 4 (2.6 mg, tR = 27 min). Fraction Fr. 2 (3.0 g) was isolated and purified by preparative HPLC with a Pursuit 5 PFP column (35% ACN in H2O, v/v, 2 mL/min) to give compound 15 (11.5 mg, tR = 12 min). Fraction Fr. 3 (40.6 g) was subjected to MPLC with MeOH and H2O (2:8–1:0, v/v, per 2.0 L) to obtain the compound 16 (908.6 mg) and nine subfractions. Subfraction Fr. 3–7 was isolated by preparative HPLC with a Titank C18 column (50% ACN in H2O, v/v, 2 mL/min) to give compound 7 (12.4 mg, tR = 16 min), compound 8 (10.2 mg, tR = 22 min), compound 13 (11.7 mg, tR = 14 min), compound 14 (9.9 mg, tR = 27 min), compound 11 (4.6 mg, tR = 17 min), compound 10 (3.4 mg, tR = 24 min) and mixture S15. Mixture S15 (15.5 mg) was isolated and purified by analytical HPLC with a chiral column (50% ACN in H2O, v/v, 0.8 mL/min) to give compounds 5 (1.0 mg, tR = 20 min), 6 (1.0 mg, tR = 22 min) and 3 (0.9 mg, tR = 24 min).
Penicacid O (1). White powder; UV (MeOH) λmax (log ε) 222 (4.54), 252 (4.08), 307 (3.82) nm; ECD (0.15 mg/mL, MeOH) λmaxε) 213 (−0.17), 225 (−1.74), 256 (0.74), 279 (−0.09), 310 (0.29) nm; 1H and 13C NMR data, see Table 1; HRESIMS m/z 291.1224 [M + H]+ (calcd for C16H19O5, 291.1227).
Penicacid P (2). White powder; UV (MeOH) λmax (log ε) 222 (4.13), 252 (3.66), 307 (3.41) nm; ECD (0.30 mg/mL, MeOH) λmaxε) 208 (−0.01), 225 (0.74), 253 (−0.50), 276 (−0.04), 313 (−0.20) nm; 1H and 13C NMR data, see Table 1; HRESIMS m/z 291.1227 [M + H]+ (calcd for C16H19O5, 291.1227).
Penicacid Q (3). White powder; UV (MeOH) λmax (log ε) 219 (4.15), 306 (3.38) nm; ECD (0.30 mg/mL, MeOH) λmaxε) 226 (1.47), 254 (−0.21), 279 (0.06), 310 (−0.43) nm; 1H and 13C NMR data, see Table 1; HRESIMS m/z 291.1227 [M+H]+ (calcd for C16H19O5, 291.1227).
Penicacid R (4). White powder; UV (MeOH) λmax (log ε) 221 (4.42), 306 (3.69) nm; ECD (0.30 mg/mL, MeOH) λmaxε) 225 (−1.18), 253 (0.19), 281 (−0.06), 312 (0.34) nm; 1H and 13C NMR data, see Table 1; HRESIMS m/z 291.1224 [M+H]+ (calcd for C16H19O5, 291.1227).
Penicacid S (5). Yellow oil; UV (MeOH) λmax (log ε) 223 (4.45), 256 (3.99), 308 (3.75) nm; ECD (0.20 mg/mL, MeOH) λmaxε) 210 (−2.28), 229 (3.93), 262 (−0.76), 278 (−0.10), 307 (−0.65) nm; 1H and 13C NMR data, see Table 2; HRESIMS m/z 333.1350 [M + H]+ (calcd for C18H21O6, 333.1333).
Penicacid T (6). Yellow oil; UV (MeOH) λmax (log ε) 222 (4.43), 254 (3.95), 308 (3.72) nm; ECD (0.20 mg/mL, MeOH) λmaxε) 211 (2.68), 230 (−4.63), 259 (0.83), 277 (0.07), 306 (0.73) nm; 1H and 13C NMR data, see Table 2; HRESIMS m/z 333.1347 [M + H]+ (calcd for C18H21O6, 333.1333).
Penicacid U (7). Yellow oil; [ α ] D 25 = −2.3 (c 0.3, MeOH); UV (MeOH) λmax (log ε) 215 (4.51), 250 (3.85), 304 (3.57) nm; ECD (0.10 mg/mL, MeOH) λmaxε) 210 (0.58), 222 (1.21), 281 (−0.20) nm; 1H and 13C NMR data, see Table 3; HRESIMS m/z 387.1414 [M + Na]+ (calcd for C19H24O7Na, 387.1414).
Penicacid V (8). Yellow oil; [ α ] D 25 = −10.3 (c 0.3, MeOH); UV (MeOH) λmax (log ε) 216 (4.57), 250 (3.89), 304 (3.62) nm; ECD (0.10 mg/mL, MeOH) λmaxε) 218 (1.55), 278 (−0.25) nm; 1H and 13C NMR data, see Table 3; HRESIMS m/z 415.1373 [M + Na]+ (calcd for C20H24O8Na, 415.1363).
Penicacid W (9). Yellow oil; UV (MeOH) λmax (log ε) 216 (4.55), 250 (3.91), 305 (3.60) nm; ECD (0.20 mg/mL, MeOH) λmaxε) 211 (0.16), 229 (−0.23), 257 (0.01) nm; 1H and 13C NMR data, see Table 3; HRESIMS m/z 415.1377 [M+Na]+ (calcd for C20H24O8Na, 415.1363).

3.4. X-Ray Crystallographic Analysis

Colorless crystals of compound 1 were obtained in PE/DCM (1:1) solution by slow evaporation at 4 °C. Similarly, colorless crystals of compound 12 were obtained in MeOH/PE/H2O (5:5:1) solution by slow evaporation at 4 °C. Their crystal data were collected from a single crystal on a Bruker D8 VENTURE dual-wavelength Mo/Cu three-circle diffractometer with a microfocus sealed X-ray tube using mirror optics as the monochromator and a Bruker PHOTON III detector. The crystallographic data of 1 and 12 were measured at 302.00 K, respectively, with CuKα radiation (λ = 1.54178 Å). The structure was solved by the direct method using SHELXT and refined by the full-matrix least-square approach against F2 by SHELXL-2019/1 [22,23]. All non-hydrogen atoms were refined with anisotropic displacement parameters. All C-bound hydrogen atoms were refined with isotropic displacement parameters. Crystallographic data of 1 and 12 (Tables S4 and S5) have been deposited in the Cambridge Crystallographic Data Centre (deposition No.: CCDC 2498064 for 1 and CCDC 2498063 for 12). These data can be obtained, free of charge, on application to CCDC, 12 Union Road, Cambridge CB21EZ, UK [fax: +44(0)-1223-336033 or e-mail: deposit@ccdc.cam.ac.uk].
Crystal data for 1. C16H18O5, Mr = 290.30, crystal size 0.228 × 0.142 × 0.015 mm3, monoclinic, a = 5.02400(10) Å, b = 13.6427(4) Å, c = 20.9641(6) Å, α = 90°, β = 96.049(2)°, γ = 90°, V = 1428.90(7) Å3, T = 302.00 K, space group P21, Z = 4, μ(Cu Kα) = 0.831 mm−1, 27,611 reflections collected, 4888 independent reflections (Rint = 0.0635, Rsigma = 0.0494). The final R1 values were 0.0466 (I ≥ 2σ(I)). The final wR2 values were 0.1347 (I ≥ 2σ(I)). The final R1 values were 0.0798 (all data). The final wR2 values were 0.1347 (all data). The goodness of fit on F2 was 1.005. The Flack parameter was −0.1(2) (Table S3).
Crystal data for 12. C16H18O5, Mr = 290.30, crystal size 0.306 × 0.02 × 0.004 mm3, monoclinic, a = 4.5267(3) Å, b = 11.7847(7) Å, c = 14.4718(9) Å, α = 71.277(4)°, β = 86.160(4)°, γ = 85.886(4)°, V = 728.48(8) Å3, T = 302.00 K, space group P 1 - , Z = 2, μ(Cu Kα) = 0.815 mm−1, 31,113 reflections collected, 2584 independent reflections (Rint = 0.0517, Rsigma = 0.0229). The final R1 values were 0.0557 (I ≥ 2σ(I)). The final wR2 values were 0.1615 (I ≥ 2σ(I)). The final R1 values were 0.0709 (all data). The final wR2 values were 0.1748 (all data). The goodness of fit on F2 was 1.093 (Table S4).

3.5. ECD Calculation

Conformational searches were carried out by means of the Maestro 12.8 software using the Molecular Merck force field. All density functional theory and time-dependent calculations were performed with the Gaussian 09 program. Conformers within a 12 kcal/mol energy window were generated and optimized by DFT calculations at the B3LYP/6-31+G (d,p) level [24].
The relative configurations of compounds 16 and 8 also underwent a series of random conformational searches using Maestro 12.8 software with MMFF. Subsequently, the low-energy conformers were re-optimized using the TD-DFT method at the B3LYP/6-31G (d,p) level in MeOH, employing the IEFPCM model in the Gaussian 09 program. Theoretical calculations for ECD were performed in MeOH at the B3LYP/6-31G (d,p) level [25]. The calculated ECD curves were generated using the SpecDis 3.0 and GraphPad Prism 8.0 from dipole length rotational strengths by applying Gaussian band shapes with a half-bandwidth ranging from 0.2 to 0.4 eV, based on the contributions of each conformer calculated via the Boltzmann distribution following UV correction.

3.6. Methylate the Phenol Group of 7 (7-R)

To a solution of 7 (10.0 mg) in CH2Cl2 (3.0 mL), excess TMSCHN2 (2 mL, 2.0 M) was added, and the mixture was stirred at room temperature (RT) for 48 h. The reaction mixture was concentrated under vacuum and purified by analytical HPLC with a Pursuit 5 PFP column (40% ACN in H2O, v/v, 2 mL/min) to furnish 3.2 mg of 7R: HRESIMS m/z 401.1583 [M+Na]+ (calcd for C20H26O7Na, 401.1571).

3.7. Preparation of the (S)- and (R)-MTPA Esters of 7R

Compound 7R (3.2 mg), 4-(dimethylamino)pyridine (1.0 mg) and (R)-MTPA-Cl were added to 400 µL stirred pyridine solution. The mixture was reacted at RT for 48 h and then dried to give (S)-MTPA ester (7Ra). (R)-MTPA ester of 7R (7Rb) was obtained by the same experimental procedure.
(S)-MTPA ester of 7R (7Ra). 1H NMR (600 MHz, CDCl3) δH 5.15 (2H, s, H2-3), 2.18 (3H, s, H3-8), 3.42 (2H, dd, J = 11.2, 7.1 Hz, H2-1′), 5.68 (1H, t, J = 6.9 Hz, H-2′), 2.82–2.54 (2H, m, H2-5′), 1.84 (3H, s, H3-7′), 4.02 (2H, qd, J = 7.2, 6.1 Hz, H2-8′), 1.16 (3H, t, J = 7.1 Hz, H3-9′), 4.02 (3H, s, H3-5-OCH3), 3.74 (3H, s, H3-7-OCH3); HRESIMS m/z 617.1979 [M + Na]+ (calcd for C30H33F3O9Na, 617.1969).
(R)-MTPA ester of 7R (7Rb). 1H NMR (600 MHz, CDCl3) δH 5.15 (2H, s, H2-3), 2.18 (3H, s, H3-8), 3.38 (2H, dd, J = 11.2, 7.1 Hz, H2-1′), 5.61 (1H, t, J = 6.8 Hz, H-2′), 2.85–2.54 (2H, m, H2-5′), 1.69 (3H, s, H3-7′), 4.09 (2H, qd, J = 7.1, 1.8 Hz, H2-8′), 1.20 (3H, t, J = 7.1 Hz, H3-9′), 4.01 (3H, s, H3-5-OCH3), 3.74 (3H, s, H3-7-OCH3); HRESIMS m/z 617.1986 [M + Na]+ (calcd for C30H33F3O9Na, 617.1969).

3.8. Biological Assay

The bioactivity of the 16 compounds and doxorubicin (MedChemExpress, Monmouth Junction, NJ, USA) against human tumor cell proliferation was assessed by the CCK-8 method, a colorimetric assay for measuring cell viability, proliferation, and cytotoxicity [26]. MOLT-3, CCRF-CEM, HT-29 and BXPC-3 were obtained from ATCC; Karpas-422 and WSU-DL-CL2 were purchased from DSMZ; MOLM-13 was obtained from JRCB; OCI-AML3 was purchased from COBIOER (Nanjing, China); and HL-60 was obtained from the National Collection of Authenticated Cell Cultures (Shanghai, China). All cells were cultured according to the recommendations. Cells were seeded in each well of 96-well plates and cultured with different concentrations of test compounds for 72 h. Then, 10 μL of CCK-8 was added per well. The absorbance of each well was measured after 2 h of incubation at 37 °C by SpectraMAX190 (Molecular Devices, San Jose, CA, USA) at 450 nm. The IC50 value was calculated by SoftMax Pro (Molecular Devices).

4. Conclusions

In summary, Penicillium senticosum RCDB005 was cultured in a solid medium and extracted with ethyl acetate (EtOAc). The resulting crude extracts were fractionated using a silica gel column and subsequently subjected to high-performance liquid chromatography (HPLC) to afford sixteen compounds including nine new MPA derivatives (19), two new natural products (10, 11), and five known compounds (1216) (Figure 2). Their structures were determined using NMR, HRESIMS and optical rotatory dispersion (ORD) spectra, electronic circular dichroism (ECD) calculations, X-ray crystallography and modified Mosher’s methods. Eight of these compounds were evaluated for anti-proliferative effects against nine human cancer cell lines, and the IC50 values ranged from nM to μM levels. Compounds 5, 79 showed potent inhibitory activity against human acute myeloid leukemia cells (MOLM-13), with IC50 values between 0.13 and 1.13 μM. This study enriched our knowledge of mycophenolic acid derivatives isolated from marine microorganisms. However, given the insufficient sample amount and the weak potency of these compounds, mechanistic studies were not performed. Our future work will focus on identifying more potent analogs to enable subsequent in-depth studies.

Supplementary Materials

The following supporting information can be downloaded at https://www.mdpi.com/article/10.3390/md24030108/s1, 16S rRNA/ITS sequences of strains; Table S1: 1H NMR and 13C NMR data for compounds 10 and 11; Table S2: IC50 values of the compounds 1–4, 6, and 10–12 against OCI-AML3 tumor cells; Tables S3 and S4: X-ray crystallographic data for 1 and 12; Figure S1: Key 1H-1H COSY, HMBC and NOESY correlations of compounds 10 and 11; Figure S2–S105: UV, NMR and HRESIMS spectra of 111.

Author Contributions

G.D., W.R. and M.-W.W. contributed to the conception and design of the study. G.D., W.R., L.L. and Y.L. (Yuan Li) performed experiments and analyzed the data. G.D. and W.R. drafted the manuscript. J.W. and M.-W.W. edited the manuscript. Q.S., Y.Z. and Y.C. performed the bioactivity assay. Y.L. (Yunan Liu), Q.P. and Q.L. obtained spectral data of the compounds. J.W. helped the identification of compounds. All authors have read and agreed to the published version of the manuscript.

Funding

This work was partially supported by Hainan Provincial Major Science and Technology Project (No. ZDKJ2021028) and the Strategic Priority Research Program of the Chinese Academy of Sciences (XDB1060401).

Institutional Review Board Statement

Not applicable.

Data Availability Statement

The data presented in this study are available upon request from the corresponding author.

Acknowledgments

The authors are grateful to W.J. Zhang and D.H. Yang for their valuable support. Additionally, we thank Sanya Science and Education Innovation Park of Wuhan University of Technology for providing access to the Rudolph Research Analytical Autopol III polarimeter.

Conflicts of Interest

The authors declare no conflicts of interest.

References

  1. Tamzi, N.N.; Rahman, M.M.; Das, S. Recent advances in marine-derived bioactives towards cancer therapy. Int. J. Transl. Med. 2024, 4, 740–781. [Google Scholar] [CrossRef]
  2. Menchinskaya, E.S.; Dyshlovoy, S.A.; Venz, S.; Jacobsen, C.; Hauschild, J.; Rohlfing, T.; Silchenko, A.S.; Avilov, S.A.; Balabanov, S.; Bokemeyer, C.; et al. Anticancer activity of the marine triterpene glycoside cucumarioside A2-2 in human prostate cancer cells. Mar. Drugs 2024, 22, 20. [Google Scholar] [CrossRef]
  3. Chen, J.-J.; Wang, S.-W.; Chiang, Y.-R.; Pang, K.-L.; Kuo, Y.-H.; Shih, T.-Y.; Lee, T.-H. Highly oxygenated constituents from a marine alga-derived fungus Aspergillus giganteus NTU967. Mar. Drugs 2020, 18, 303. [Google Scholar] [CrossRef]
  4. El-Seedi, H.R.; Refaey, M.S.; Elias, N.; El-Mallah, M.F.; Albaqami, F.M.K.; Dergaa, I.; Du, M.; Salem, M.F.; Tahir, H.E.; Daglia, M.; et al. Marine natural products as a source of novel anticancer drugs: An updated review (2019–2023). Nat. Prod. Bioprospect. 2025, 15, 13. [Google Scholar] [CrossRef]
  5. Zhang, Q.; Yang, B.; Li, F.; Liu, M.; Lin, S.; Wang, J.; Xue, Y.; Zhu, H.; Sun, W.; Hu, Z.; et al. Mycophenolic acid derivatives with immunosuppressive activity from the coral-derived fungus Penicillium bialowiezense. Mar. Drugs 2018, 16, 230. [Google Scholar] [CrossRef] [PubMed]
  6. Blunt, J.W.; Carroll, A.R.; Copp, B.R.; Davis, R.A.; Keyzers, R.A.; Prinsep, M.R. Marine natural products. Nat. Prod. Rep. 2018, 35, 8–53. [Google Scholar] [CrossRef] [PubMed]
  7. Habib, E.; León, F.; Dauer, J.; Hill, R.; Carvalho, P.; Cutler, H.; Cutler, S. Mycophenolic derivatives from Eupenicillium parvum. J. Nat. Prod. 2008, 71, 1915–1918. [Google Scholar] [CrossRef]
  8. Bentley, R. Mycophenolic acid: A one hundred year odyssey from antibiotic to immunosuppressant. Chem. Rev. 2000, 100, 3801–3825. [Google Scholar] [CrossRef]
  9. Chen, X.; Zhou, G.; Sun, C.; Zhang, X.; Zhang, G.; Zhu, T.; Li, J.; Che, Q.; Li, D. Penicacids E-G, three new mycophenolic acid derivatives from the marine-derived fungus Penicillium parvum HDN17-478. Chin. J. Nat. Med. 2020, 18, 850–854. [Google Scholar] [CrossRef] [PubMed]
  10. Noto, T.; Sawada, M.; Ando, K.; Koyama, K. Some biological properties of mycophenolic acid. J. Antibiot. 1969, 22, 165–169. [Google Scholar] [CrossRef]
  11. Williams, R.; Lively, D.; Delong, D.; Cline, J.; Sweeney, M.; Poore, G.; Larsen, S. Mycophenolic acid—Antiviral and antitumor properties. J. Antibiot. 1968, 21, 429–435. [Google Scholar] [CrossRef]
  12. Song, X.; Tu, R.; Mei, X.; Wu, S.; Lan, B.; Zhang, L.; Luo, X.; Liu, J.; Luo, M. A mycophenolic acid derivative from the fungus Penicillium sp. SCSIO sof101. Nat. Prod. Res. 2020, 34, 1206–1212. [Google Scholar] [CrossRef]
  13. Mo, T.; Qin, Y.; Zhang, Y.; Liang, Y.; Li, X.; Li, W.; Chen, G. Three new antibacterial mycophenolic acid derivatives from the marine-derived fungus Penicillium sp. HN-66. Chem. Biodivers. 2025, 22, e202401657. [Google Scholar] [CrossRef] [PubMed]
  14. Li, F.; Ye, Z.; Huang, Z.; Chen, X.; Sun, W.; Gao, W.; Zhang, S.; Cao, F.; Wang, J.; Hu, Z.; et al. New α-pyrone derivatives with herbicidal activity from the endophytic fungus Alternaria brassicicola. Bioorg. Chem. 2021, 117, 105452. [Google Scholar] [CrossRef] [PubMed]
  15. Hoye, T.R.; Jeffrey, C.S.; Shao, F. Mosher ester analysis for the determination of absolute configuration of stereogenic (chiral) carbinol carbons. Nat. Protoc. 2007, 2, 2451–2458. [Google Scholar] [CrossRef]
  16. Peng, Q.; Huang, W.; Zhang, X.; Pang, X.; Liu, Y.; Ruan, W.; Li, Q.; Ding, L.; Jin, H.; Yang, D.; et al. Structurally diverse new metabolites from three hadal trench-derived microorganisms. ACS Omega 2025, 10, 6201–6209. [Google Scholar] [CrossRef]
  17. Ubukata, M.; Takamori, H.; Ohashi, M.; Mitsuhashi, S.; Yamashita, K.; Asada, T.; Nakajima, N.; Matsuura, N.; Tsuruga, M.; Taki, K.; et al. Mycophenolic acid as a latent agonist of PPARγ. Bioorg. Med. Chem. Lett. 2007, 17, 4767–4770. [Google Scholar] [CrossRef] [PubMed]
  18. Brookes, P.; Cordes, J.; White, A.; Barrett, A. Total synthesis of mycophenolic acid by a palladium-catalyzed decarboxylative allylation and biomimetic aromatization sequence. Eur. J. Org. Chem. 2013, 32, 7313–7319. [Google Scholar] [CrossRef]
  19. Lu, X.; Zheng, Z.; Zhang, H.; Huo, C.; Dong, Y.; Ma, Y.; Ren, X.; Ke, A.; He, J.; Gu, Y.; et al. Two new members of mycophenolic acid family from Penicillium brevicompactum Dierckx. J. Antibiot. 2009, 62, 527–529. [Google Scholar] [CrossRef]
  20. Chen, Z.; Zheng, Z.; Huang, H.; Song, Y.; Zhang, X.; Ma, J.; Wang, B.; Zhang, C.; Ju, J. Penicacids A–C, three new mycophenolic acid derivatives and immunosuppressive activities from the marine-derived fungus Penicillium sp. SOF07. Bioorg. Med. Chem. Lett. 2012, 22, 5424–5427. [Google Scholar] [CrossRef]
  21. Elsebai, M. Secondary metabolites from the marine-derived fungus Phaeosphaeria spartinae. Nat. Prod. Res. 2021, 35, 1504–1509. [Google Scholar] [CrossRef]
  22. Sheldrick, G. Crystal structure refinement with SHELXL. Acta Crystallogr. Sect. C-Struct. Chem. 2015, 71, 3–8. [Google Scholar] [CrossRef]
  23. Sheldrick, G. SHELXT—Integrated space-group and crystal-structure determination. Acta Crystallogr. Sect. A-Found. Adv. 2015, 71, 3–8. [Google Scholar] [CrossRef] [PubMed]
  24. Ren, J.; Ding, S.-S.; Zhu, A.; Cao, F.; Zhu, H.-J. Bioactive azaphilone derivatives from the fungus Talaromyces aculeatus. J. Nat. Prod. 2017, 80, 2199–2203. [Google Scholar] [CrossRef] [PubMed]
  25. Wang, Y.; Zhou, X.M.; Du, J.-f.; Xu, X.F.; Song, X.M. A novel lactam and two rare mycophenolic acid derivatives from the fungus Penicillium sclerotiorum JBHL321. Chem. Biodivers. 2024, 22, e202401962. [Google Scholar] [CrossRef]
  26. Cai, L.; Qin, X.; Xu, Z.; Song, Y.; Jiang, H.; Wu, Y.; Ruan, H.; Chen, J. Comparison of cytotoxicity evaluation of anticancer drugs between real-Time cell analysis and CCK-8 method. ACS Omega 2019, 4, 12036–12042. [Google Scholar] [CrossRef] [PubMed]
Figure 1. Key 1H-1H COSY, HMBC and NOESY correlations of compounds 19.
Figure 1. Key 1H-1H COSY, HMBC and NOESY correlations of compounds 19.
Marinedrugs 24 00108 g001
Figure 2. Structures of compounds 116.
Figure 2. Structures of compounds 116.
Marinedrugs 24 00108 g002
Figure 3. Experimental and calculated ECD curves of compounds 14.
Figure 3. Experimental and calculated ECD curves of compounds 14.
Marinedrugs 24 00108 g003
Figure 4. The diamond view of compounds 1 and 12.
Figure 4. The diamond view of compounds 1 and 12.
Marinedrugs 24 00108 g004
Figure 5. Experimental and calculated ECD curves of compounds 5, 6 and 8.
Figure 5. Experimental and calculated ECD curves of compounds 5, 6 and 8.
Marinedrugs 24 00108 g005
Figure 6. ΔδH(SR) (in ppm) values for the MTPA esters of compound 7.
Figure 6. ΔδH(SR) (in ppm) values for the MTPA esters of compound 7.
Marinedrugs 24 00108 g006
Table 1. 1H NMR (600 MHz) and 13C NMR (150 MHz) data for compounds 14 in CD3OD.
Table 1. 1H NMR (600 MHz) and 13C NMR (150 MHz) data for compounds 14 in CD3OD.
1234
Position IonδC, TypeδH (J in Hz)δC, TypeδH (J in Hz)δC, TypeδH (J in Hz)δC, TypeδH (J in Hz)
1171.4, C 171.4, C 171.5, C 171.5, C
370.7, CH25.22, s70.7, CH25.22, s70.7, CH25.22, s70.7, CH25.22, s
3a148.8, C 148.8, C 148.8, C 148.8, C
4116.3, C 116.3, C 116.2, C 116.2, C
5161.7, C 161.7, C 161.7, C 161.7, C
5-OCH359.7, CH34.00, s59.7, CH34.00, s59.7, CH33.98, s59.7, CH33.98, s
6117.0, C 117.0, C 117.2, C 117.2, C
7158.7, C 158.7, C 158.9, C 158.9, C
7a102.9, C 102.9, C 102.8, C 102.8, C
811.0, CH32.06, s11.0, CH32.07, s11.0, CH32.06, s11.0, CH32.06, s
1′32.3, CH23.58, dd (15.4, 9.3); 3.21, dd (15.5, 9.3)32.3, CH23.58, dd (15.5, 9.2); 3.20, dd (15.5, 9.2)32.9, CH23.59, dd (15.5, 9.4); 3.19, dd (15.5, 9.4)32.9, CH23.59, dd (15.6, 9.4); 3.19, dd (15.6, 9.4)
2′88.0, CH5.13, q (7.9)88.0, CH5.13, q (7.9)87.7, CH5.16, q (7.2)87.7, CH5.16, q (7.2)
3′52.4, CH3.08, p (7.2)52.4, CH3.08, p (7.2)52.7, CH3.08, p (7.0)52.7, CH3.07, p (7.0)
4′212.3, C 212.3, C 212.2, C 212.2, C
5′29.8, CH32.27, s29.8, CH32.27, s29.6, CH32.23, s29.6, CH32.23, s
6′12.1, CH31.16, d (7.0)12.1, CH31.16, d (7.0)12.7, CH31.28, d (7.1)12.7, CH31.28, d (7.1)
Table 2. 1H NMR (600 MHz) and 13C NMR (150 MHz) data for compounds 5 and 6 in CDCl3.
Table 2. 1H NMR (600 MHz) and 13C NMR (150 MHz) data for compounds 5 and 6 in CDCl3.
56
PositionδC, TypeδH (J in Hz)δC, TypeδH (J in Hz)
1169.2, C 169.2, C
2
369.2, CH25.13, s69.2, CH25.13, s
3a147.2, C 147.2, C
4114.9, C 114.9, C
5159.9, C 159.9, C
5-OCH359.3, CH33.95, s59.3, CH33.95, s
6116.2, C 116.2, C
7158.1, C 158.1, C
7a102.7, C 102.7, C
811.2, CH32.06, s11.2, CH32.06, s
1′33.1, CH23.52, dd (15.5, 8.1); 3.20, dd (15.5, 8.1)33.1, CH23.52, dd (15.5, 8.0); 3.20, dd (15.5, 8.0)
2′90.1, CH5.40, t (8.1)90.1, CH5.40, t (8.1)
3′136.5, C 136.5, C
4′120.8, CH5.79, t (7.1)120.8, CH5.79, t (7.1)
5′33.3, CH23.12, d (7.1)33.3, CH23.12, d (7.1)
6′172.0, C 172.0, C
7′11.4, CH31.68, s11.4, CH31.68, s
8′52.1, CH33.7, s52.1, CH33.7, s
Table 3. 1H NMR (600 MHz) and 13C NMR (150 MHz) data for compounds 8 in CD3OD, 7 and 9 in CDCl3.
Table 3. 1H NMR (600 MHz) and 13C NMR (150 MHz) data for compounds 8 in CD3OD, 7 and 9 in CDCl3.
789
PositionδC, TypeδH (J in Hz)δC, TypeδH (J in Hz)δC, TypeδH (J in Hz)
1173.0, C 173.7, C 172.9, C
370.2, CH25.19, s70.8, CH25.25, s70.2, CH25.20, s
3a144.3, C 147.0, C 144.6, C
4116.9, C 117.9, C 117.0, C
5163.9, C 164.9, C 163.8, C
5-OCH361.2, CH33.76, s61.6, CH33.76, s61.3, CH33.77, s
6121.7, C 122.7, C 121.1, C
7153.8, C 154.7, C 153.7, C
7a106.5, C 107.8, C 106.6, C
811.7, CH32.14, s11.4, CH31.98, s11.7, CH32.15, s
1′22.4, CH23.42, dd (7.2, 3.1)23.2, CH23.42, d (7.1)22.6, CH23.49, d (7.1)
2′124.2, CH5.55, t (7.1)128.2, CH5.56, t (6.5)128.8, CH5.51, t (7.4)
3′136.1, C 133.6, C 133.0, C
4′73.3, CH4.42, dd (9.3, 3.6)76.7, CH5.47, dd (8.7, 5.4)30.5, CH22.46–2.38, overlapped
5′40.3, CH22.59–2.46, m39.2, CH22.72–2.59, m33.0, CH22.46–2.38, overlapped
6′172.8, C 172.3, C 173.6, C
7′12.3, CH31.82, s12.3, CH31.82, s62.0, CH24.82, s
8′60.9, CH24.13, qd (7.2, 1.4)52.2, CH33.59, s51.7, CH33.61, s
9′14.3, CH31.24, t (7.2)171.7, C 171.2, C
10′ 20.9, CH32.16, s21.2, CH32.10, s
Table 4. IC50 values of the eight compounds against human tumor cell lines.
Table 4. IC50 values of the eight compounds against human tumor cell lines.
Cpd.IC50 (Means, μM)
Hematologic Tumor CellSolid Tumor Cell
MOLM-13MOLT-3OCI-AML3KARPAS-422WSU-DL-CL2CCRF-CEMHL-60HT-29BXPC-3
50.15 ± 0.022.43 ± 0.192.11 ± 0.5210.87 ± 0.6518.74 ± 3.7914.11 ± 1.3321.90 ± 2.4122.87 ± 0.25>40
70.13 ± 0.012.95 ± 0.121.31 ± 0.5914.13 ± 0.8417.48 ± 4.2918.1 ± 2.6522.43 ± 4.2221.98 ± 6.46>40
80.14 ± 0.011.35 ± 0.301.73 ± 0.457.04 ± 0.768.53 ± 0.5910.44 ± 0.9512.76 ± 1.3915.58 ± 2.4032.57 ± 9.15
91.13 ± 0.0313.22 ± 0.6913.25 ± 2.8333.18 ± 7.35>40>40>40>40>40
130.48 ± 0.040.48 ± 0.203.17 ± 0.242.68 ± 0.221.07 ± 0.261.17 ± 0.122.97 ± 0.893.01 ± 0.4913.98 ± 4.55
140.24 ± 0.040.43 ± 0.033.3 ± 0.803.67 ± 0.94≤0.572.19 ± 1.122.46 ± 1.939.01 ± 2.51>40
152.89 ± 0.190.84 ± 0.1617.93 ± 1.168.11 ± 0.396.42 ± 1.965.98 ± 0.1531.36 ± 8.1628.84 ± 7.93>40
160.06 ± 0.021.39 ± 0.041.22 ± 0.396.20 ± 0.748.12 ± 1.6311.14 ± 1.4512.28 ± 1.9215.50 ± 2.96>40
DOX0.01 ± 0.003ND0.05 ± 0.010.12 ± 0.090.05 ± 0.030.03 ± 0.0040.04 ± 0.0030.17 ± 0.050.27 ± 0.02
Cpd., compound; DOX: doxorubicin; ND: not determined.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Deng, G.; Ruan, W.; Li, Q.; Peng, Q.; Liu, Y.; Lin, L.; Li, Y.; Shen, Q.; Zhao, Y.; Wang, J.; et al. Novel Marine Fungus-Derived Mycophenolic Acids That Inhibit Acute Myeloid Leukemia Cell Proliferation. Mar. Drugs 2026, 24, 108. https://doi.org/10.3390/md24030108

AMA Style

Deng G, Ruan W, Li Q, Peng Q, Liu Y, Lin L, Li Y, Shen Q, Zhao Y, Wang J, et al. Novel Marine Fungus-Derived Mycophenolic Acids That Inhibit Acute Myeloid Leukemia Cell Proliferation. Marine Drugs. 2026; 24(3):108. https://doi.org/10.3390/md24030108

Chicago/Turabian Style

Deng, Guangli, Wu Ruan, Qun Li, Qingyun Peng, Yunan Liu, Lingbin Lin, Yuan Li, Qianqian Shen, Yangrong Zhao, Junfeng Wang, and et al. 2026. "Novel Marine Fungus-Derived Mycophenolic Acids That Inhibit Acute Myeloid Leukemia Cell Proliferation" Marine Drugs 24, no. 3: 108. https://doi.org/10.3390/md24030108

APA Style

Deng, G., Ruan, W., Li, Q., Peng, Q., Liu, Y., Lin, L., Li, Y., Shen, Q., Zhao, Y., Wang, J., Chen, Y., & Wang, M.-W. (2026). Novel Marine Fungus-Derived Mycophenolic Acids That Inhibit Acute Myeloid Leukemia Cell Proliferation. Marine Drugs, 24(3), 108. https://doi.org/10.3390/md24030108

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop